Reach Neuro

Overview

Reach Neuro is a biotechnology company developing brain-computer interface (BCI) technologies for the treatment of neurological conditions, with a primary focus on stroke rehabilitation and motor recovery. Founded in 2021 and headquartered in Pittsburgh, Pennsylvania, Reach Neuro develops implantable neural interfaces that enable patients to regain motor function after stroke[@reach].

The company's flagship product, the ReNeuro system, is a minimally invasive brain-computer interface designed to decode neural signals and stimulate targeted brain regions to promote neuroplasticity and functional recovery in stroke patients[@bci].

Technology Overview

ReNeuro System

The Reach Neuro ReNeuro system consists of:

| Component | Description |
|-----------|-------------|
| Neural Array | 64-channel microelectrode array |
| Implant | Miniaturized wireless transmitter |
| External Unit | Signal processing and control |
| Stimulation | Integrated electrical stimulation |
| Software | Machine learning decoder |

Technology Features

• Bidirectional BCI: Records neural activity and delivers targeted stimulation
• Wireless design: Fully implantable, no percutaneous connections
• Chronic implantation: Designed for long-term use
• Adaptive algorithms: Personalized decoder adaptation

Mechanism of Action

The ReNeuro system works through several mechanisms:

Overview

Reach Neuro is a biotechnology company developing brain-computer interface (BCI) technologies for the treatment of neurological conditions, with a primary focus on stroke rehabilitation and motor recovery. Founded in 2021 and headquartered in Pittsburgh, Pennsylvania, Reach Neuro develops implantable neural interfaces that enable patients to regain motor function after stroke[@reach].

The company's flagship product, the ReNeuro system, is a minimally invasive brain-computer interface designed to decode neural signals and stimulate targeted brain regions to promote neuroplasticity and functional recovery in stroke patients[@bci].

Technology Overview

ReNeuro System

The Reach Neuro ReNeuro system consists of:

| Component | Description |
|-----------|-------------|
| Neural Array | 64-channel microelectrode array |
| Implant | Miniaturized wireless transmitter |
| External Unit | Signal processing and control |
| Stimulation | Integrated electrical stimulation |
| Software | Machine learning decoder |

Technology Features

• Bidirectional BCI: Records neural activity and delivers targeted stimulation
• Wireless design: Fully implantable, no percutaneous connections
• Chronic implantation: Designed for long-term use
• Adaptive algorithms: Personalized decoder adaptation

Mechanism of Action

The ReNeuro system works through several mechanisms:

Clinical Programs

Stroke Rehabilitation

Reach Neuro's primary indication is chronic stroke motor recovery:

| Study | Phase | Participants | Status |
|-------|-------|--------------|--------|
| REBUILD | Feasibility | 10 patients | Completed |
| RECOVER | Pilot | 30 patients | Recruiting |
| RESTORE | Pivotal | 150 patients | Planned |

Target Population

• Indication: Motor deficits following ischemic or hemorrhagic stroke
• Timing: Chronic phase (>6 months post-stroke)
• Severity: Moderate to severe motor impairment
• Age: 18-75 years

Clinical Outcomes

Primary endpoints:

• Upper extremity Fugl-Meyer Assessment (UE-FMA) improvement
• Wolf Motor Function Test (WMFT) performance
• Quality of life measures (SF-36)

Competitive Landscape

Stroke Recovery BCI

Reach Neuro competes in the neurorehabilitation BCI space:

| Company | Product | Technology | Stage |
|---------|---------|------------|-------|
| MindMaze | MindMotion | VR+BCI | Commercial |
| Motus | HandTutor | Robotic+BCI | Commercial |
| Reach Neuro | ReNeuro | Implantable | Clinical |
| Synchron | Stentrode | Vascular BCI | Clinical |

Technology Differentiation

| Feature | Reach Neuro Advantage |
|---------|----------------------|
| Bidirectional | Recording + stimulation |
| Spatial resolution | High-density arrays |
| Plasticity induction | Coordinated stimulation |
| Chronic use | Long-term implantation |

Regulatory Status

• FDA: Breakthrough Device Designation (2023)
• [IDE](/entities/insulin-degrading-enzyme): Investigational Device Exemption approved
• Clinical trials: RECOVER study ongoing
• EU: CE Mark application planned

Company Information

Funding

• Total raised: $45 million (Series A: $20M, Series B: $25M)
• Investors: Healthcare-focused VCs
• Valuation: ~$150 million

Key Personnel

• CEO: Dr. Emily Zhang
• CSO: Dr. John Stevens (CMU faculty)
• VP Engineering: Dr. David Park

Academic Partners

• Carnegie Mellon University (founders from CMU neuroscience)
• University of Pittsburgh Medical Center
• ShirleyAbility Lab

Pipeline Summary

| Program | Indication | Stage | Timeline |
|---------|------------|-------|----------|
| ReNeuro | Chronic stroke | IDE approved | Ongoing trials |
| ReNeuro-PD | Parkinson's disease | Preclinical | 2026 |
| ReNeuro-TBI | Traumatic brain injury | Discovery | 2027 |

Cross-References

• [Brain-Computer Interface](/companies/bci-companies)
• [Stroke Rehabilitation](/therapeutics/focused-ultrasound-neurodegeneration)
• [Neural Stimulation](/therapeutics/focused-ultrasound-neurodegeneration)
• [Neuroplasticity](/mechanisms/neuroplasticity)

See Also

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Stroke](/diseases/stroke)
• [Neuromodulation](/therapeutics/focused-ultrasound-neurodegeneration)

External Links

• [Reach Neuro Website](https://reachneuro.com)
• [ClinicalTrials.gov](https://clinicaltrials.gov)
• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)

References